TD Private Client Wealth’s Alnylam Pharmaceuticals ALNY Stock Holding History

TD Private Client Wealth’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.4K	Buy	61 +2	+3%	+$603	﹤0.01%	1047
2026 Q1	$19.5K	Buy	59 +56	+1,867%	+$19.1K	﹤0.01%	1014
2025 Q4	$1.19K	Hold	3	–	–	﹤0.01%	1343
2025 Q3	$1.37K	Buy	3 +2	+200%	+$814	﹤0.01%	1290
2025 Q2	$326	Hold	1	–	–	﹤0.01%	1360
2025 Q1	$270	Buy	+1	New	+$257	﹤0.01%	1367
2023 Q3	–	Sell	-9	Closed	-$1.71K	–	1215
2023 Q2	$1.71K	Hold	9	–	–	﹤0.01%	1178
2023 Q1	$1.8K	Hold	9	–	–	﹤0.01%	1161
2022 Q4	$2.14K	Hold	9	–	–	﹤0.01%	1114
2022 Q3	$1.8K	Hold	9	–	–	﹤0.01%	1117
2022 Q2	$1.31K	Hold	9	–	–	﹤0.01%	1160
2022 Q1	$1.47K	Sell	9 -6	-40%	-$914	﹤0.01%	1188
2021 Q4	$2.54K	Sell	15 -18	-55%	-$3.35K	﹤0.01%	996
2021 Q3	$6.23K	Hold	33	–	–	﹤0.01%	944
2021 Q2	$5.59K	Hold	33	–	–	﹤0.01%	949
2021 Q1	$4.66K	Hold	33	–	–	﹤0.01%	934
2020 Q4	$4.29K	Sell	33 -45	-58%	-$6.01K	﹤0.01%	903
2020 Q3	$11.4K	Hold	78	–	–	﹤0.01%	780
2020 Q2	$11.6K	Hold	78	–	–	﹤0.01%	785
2020 Q1	$8.49K	Buy	78 +3	+4%	+$346	﹤0.01%	771
2019 Q4	$8.64K	Buy	+75	New	+$7.48K	﹤0.01%	768

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TD Private Client Wealth's ALNY Position: Q2 2026 in Review

TD Private Client Wealth increased its Alnylam Pharmaceuticals (ALNY) stake by 3.4% in Q2 2026, buying an estimated $603 and bringing the position to 61 shares worth $18.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1047.

TD Private Client Wealth first reported a position in ALNY in Q4 2019 and has held it in 21 quarters since. The position peaked at $19.5K in Q1 2026. 789 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

TD Private Client Wealth held 61 shares of Alnylam Pharmaceuticals worth $18.4K as of Q2 2026.
TD Private Client Wealth bought 2 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $603.
Alnylam Pharmaceuticals made up ﹤0.01% of TD Private Client Wealth's portfolio in Q2 2026, its #1047 holding.
TD Private Client Wealth first reported a position in Alnylam Pharmaceuticals in Q4 2019 and has held it in 21 quarters since.
TD Private Client Wealth's Alnylam Pharmaceuticals position peaked at $19.5K in Q1 2026.
789 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on TD Private Client Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.